Journal of nuclear medicine : official publication, Society of Nuclear Medicine
-
Clinical Trial
A Prospective Study on 18F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer.
18F-DCFPyL (2-(3-{1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid), a prostate-specific membrane antigen-targeting radiotracer, has shown promise as a prostate cancer imaging radiotracer. We evaluated the safety, sensitivity, and impact on patient management of 18F-DCFPyL in the setting of biochemical recurrence of prostate cancer. Methods: Subjects with prostate cancer and biochemical recurrence after radical prostatectomy or curative-intent radiotherapy were included in this prospective study. ⋯ Twenty-two subjects reported mild adverse events after the scan; all resolved completely. Conclusion: 18F-DCFPyL PET/CT is safe and sensitive for the localization of biochemical recurrence of prostate cancer. This test improved decision making for referring oncologists and changed management for most subjects.
-
A limitation of using 68Ga-labeled prostate-specific membrane antigen (68Ga-PSMA) for detection and staging of prostate cancer is a frequently observed halo artifact around the urinary bladder caused by inaccurate scatter correction (SC) of PET data. The aim of this study was to investigate the impact of unrenormalized absolute SC on 68Ga-PSMA PET quantification in PET/MRI of the prostate in 100 patients. Methods: The PET data of 100 patients were reconstructed twice using standard SC and improved unrenormalized SC. ⋯ The mean increase using unrenormalized SC in SUVmean was 17.5% for lesions inside the halo margin (38 lesions) and 6.9% for lesions outside the halo margin (36 lesions). Conclusion: For PET/MRI of prostate cancer using 68Ga-PSMA, a proper SC is important to ensure the best possible diagnostic quality and PET quantification. Unrenormalized absolute SC significantly reduces the halo artifact around the bladder and improves PET/MRI of the prostate.
-
Comparative Study
Comparison of Static and Dynamic 18F-FDG PET/CT for Quantification of Pulmonary Inflammation in Acute Lung Injury.
PET imaging with 18F-FDG followed by mathematic modeling of the pulmonary uptake rate (Ki) is the gold standard for assessment of pulmonary inflammation in experimental studies of acute respiratory distress syndrome (ARDS). However, dynamic PET requires long imaging and allows the assessment of only 1 cranio-caudal field of view (∼15 cm). We investigated whether static 18F-FDG PET/CT and analysis of SUV or standardized uptake ratios (SURstat, uptake time-corrected ratio of 18F-FDG concentration in lung tissue and blood plasma) might be an alternative to dynamic 18F-FDG PET/CT and Patlak analysis for quantification of pulmonary inflammation in experimental ARDS. ⋯ Compared with Ki, SURstat and SUV tracked the same direction of change in regional lung inflammation in 98.6% and 84.3% of measurements, respectively. Conclusion: The Ki-SURstat correlations were considerably stronger than the Ki-SUV correlations. The good Ki-SURstat correlations suggest that static 18F-FDG PET/CT and SURstat analysis provides an alternative to dynamic 18F-FDG PET/CT and Patlak analysis, allowing the assessment of inflammation of whole lungs, repeated measurements within the period of 18F-FDG decay, and faster data acquisition.